OVAS begins trading as MLND at the open on Monday: https://www.businesswire.com/news/home/20181207005260/en/Millendo-Therapeutics-Announces-Successful-Merger-Completion This is a consequence of a reverse merger announced in Aug 2018 (#msg-142796422).